Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation

Infection, Genetics and Evolution

Volumn 20, Issue , 2013, Pages 418-421

  Rose, Rebecca ^a   Markov, Peter V ^a   Lam, Tommy T ^a   Pybus, Oliver G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Co evolution; Hepatitis C virus; IFNL3; Phylogeny; SNPs

Indexed keywords

RECOMBINANT INTERFERON;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CENTRAL AFRICA; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; MUTATION RATE; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS CELL INTERACTION; VIRUS MUTATION;

HEPATITIS C VIRUS;

CO-EVOLUTION; HEPATITIS C VIRUS; IFNL3; PHYLOGENY; SNPS;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN;

EID: 84886850346     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2013.09.029     Document Type: Article

References (28)

1. Antaki N., Bibert S., Kebbewar K., Asaad F., Baroudi O., et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012, 61:1640-1641.
2. Chen Y., Xu H.X., Wang L.J., Liu X.X., Mahato R.I., et al. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment. Pharmacol. Ther. 2012, 36:91-103.
3. Drexler J.F., Corman V.M., Müller M.A., Lukashev A.N., Gmyl A., et al. Evidence for novel hepaciviruses in rodents. PLoS Pathog. 2013, 9:e1003438.
4. Gaudieri S., Rauch A., Park L.P., Freitas E., Herrmann S., et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J. Virol. 2006, 80:11094-11104.
5. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
6. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B., et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
7. Gould S., Vrba E. Exaptation - a missing term in the science of form. Paleobiology 1982, 4-15.
8. Jeannel D., Fretz C., Traore Y., Kohdjo N., Bigot A., et al. Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J. Med. Virol. 1998, 55:92-97.
9. Kamal S.M., Nasser I.A. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008, 47:1371-1383.
10. Kapoor A., Simmonds P., Scheel T.K., Hjelle B., Cullen J.M., et al. Identification of rodent homologs of hepatitis C virus and pegiviruses. mBio. 2013, 4:e00216-00213.
11. Kawashima Y., Pfafferott K., Frater J., Matthews P., Payne R., et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009, 458:641-645.
12. Mangia A., Thompson A.J., Santoro R., Piazzolla V., Tillmann H.L., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827. (827.e821).
13. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
14. Markov P., Pepin J., Frost E., Deslandes S., Labbé A., et al. Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J. Gen. Virol. 2009, 90:2086-2096.
15. Muir A., Bornstein J., Killenberg P. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 2004, 350:2265-2271.
16. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013, 45:164-171.
17. Pybus O.G., Gray R.R. The virus whose family expanded. Nature 2013, 498:310.
18. Pybus O.G., Markov P.V., Wu A., Tatem A.J. Investigating the endemic transmission of the hepatitis C virus. Int. J. Parasitol. 2007, 37:839-849.
19. Pybus O.G., Barnes E., Taggart R., Lemey P., Markov P., et al. Genetic history of hepatitis C virus in East Asia. J. Virol. 2009, 83:1071-1082.
20. Quan P.L., Firth C., Conte J.M., Williams S.H., Zambrana-Torrelio C.M., et al. Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:8194-8199.
21. Salemi M., Vandamme A. Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J. Mol. Evol. 2002, 54:62-70.
22. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., Christen V., Terracciano L., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7034-7039.
23. Seto W.K., Tanaka Y., Liu K., Lai C.L., Yuen M.F. The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6. Am. J. Gastroenterol. 2011, 106:1007-1008.
24. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 2004, 85:3173-3188.
25. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
26. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
27. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(120-129):e118.
28. Younossi Z.M., Birerdinc A., Estep M., Stepanova M., Afendy A., et al. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J. Transl. Med. 2012, 10:25.